Evidence map›Paper›PMID 41178925›Full record

ReviewWorld journal of clinical oncology2025

Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives.

Vilma Pacheco-Barcia, Axel Mariño-Mendez, Enrique Hernandez-Jimenez, Paula Jimenez-Fonseca, Andrés Jesús Muñoz Martín, Sara Custodio-Cabello, Magda Palka-Kotlowska, Ivan Gonzalez-Diaz, Luis Cabezon-Gutierrez

Abstract readReview
In one paragraph

Review in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vilma Pacheco-BarciaDepartment of Medical Oncology, Hospital Universitario de Torrejon, Madrid 28850, Spain.
Axel Mariño-MendezDepartment of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo 33011, Spain.
Enrique Hernandez-JimenezDepartment of Research and Development, Loop Diagnostics, Barcelona 08005, Catalonia, Spain.
Paula Jimenez-FonsecaDepartment of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo 33011, Spain.
Andrés Jesús Muñoz MartínDepartment of Medical Oncology, Hospital General Universitario Gregorio Marañón, Universidad Complutense Madrid, Madrid 28007, Spain.
Sara Custodio-CabelloDepartment of Medical Oncology, Hospital Universitario de Torrejon, Madrid 28850, Spain.
Magda Palka-KotlowskaDepartment of Medical Oncology, Hospital Universitario de Torrejon, Madrid 28850, Spain.
Ivan Gonzalez-DiazDepartment of Gynecology, Hospital Universitario Severo Ochoa, Leganes 28914, Madrid, Spain.
Luis Cabezon-GutierrezDepartment of Medical Oncology, Hospital Universitario de Torrejon, Madrid 28850, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal malignancies, particularly pancreatobiliary and gastroesophageal cancers, are associated with poor prognosis due to their frequent late-stage diagnosis. Many of these tumors contribute to anorexia-cachexia syndrome and malnutrition, further exacerbating disease progression. Inflammation plays a crucial role in tumor proliferation, and growing evidence suggests that gut microbiome significantly influence inflammatory responses and clinical outcomes in these patients. Additionally, the gut microbiome contributes to carcinogenesis through multiple mechanisms, including DNA damage, activation of oncogenic pathways, and modulation of immune responses. The emerging field of nutritional interventions highlight the microbiome's impact on anticancer drug responses, affecting both chemotherapy and molecular-targeted treatments. Given its pivotal role, microbiome modulation through probiotics, fecal microbiome transplantation, and antibiotics represents a promising approach for cancer prevention and treatment. In this review, we explore the intricate interplay between gut microbiome, inflammation, and nutritional status in gastrointestinal cancers, emphasizing potential therapeutic strategies to improve patient outcomes.

Indexed as

CarcinogenesisGastrointestinal cancerGut microbiomeNutritional interventionsProbioticsTherapeutic approach

Identifiers

PMID41178925
PMCPMC12576539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.